1. Home
  2. Azioni
  3. Regno Unito
  4. London Stock Exchange
  5. GSK plc
  6. SocietÓ
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Rapporto
Tempo differito London Stock Exchange  -  17:35 12/08/2022
1450.00 GBX   +3.57%
12/08Gli ADR europei si muovono leggermente al ribasso nel venerdì di trading
MT
12/08I titoli biotecnologici ripongono le loro speranze di rimbalzo nella spinta dell'M&A
MR
12/08EUROPA: Borse Europa, in rialzo con rimbalzo titoli healthcare, bene settore viaggi
RE
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietÓFinanzaConsensusRevisioniDerivati 
AttivitÓ
Logo GSK plc
GSK plc (ex GlaxoSmithKline plc) Ŕ il gruppo farmaceutico numero 2 al mondo. Le vendite nette sono cosý suddivise per famiglia di prodotti:
- prodotti farmaceutici (52%): destinati principalmente all'infezione da HIV (26,9% delle vendite nette), alle malattie respiratorie (16,1%), ai disturbi del sistema immunitario (5%) e al cancro (2,8%);
- OTC e parafarmaci (28,1%);
- vaccini (19,9%).
Le vendite nette sono distribuite geograficamente come segue: Regno Unito (2,9%), Stati Uniti (44,2%) e altro (52,9%).

Numero di dipendenti : 90 096 persone.
Vendite per attivitÓ
20202021Delta
Pharmaceuticals17 056.0050%17 729.0052% +3.95%
Consumer Healthcare10 033.0029.4%9 607.0028.2% -4.25%
Vaccines6 982.0020.5%6 778.0019.9% -2.92%
Corporate and Other Unallocated28.000.1%---
GBP in Milioni
Vendite per regione
20202021Delta
United States14 556.0042.7%15 093.0044.2% +3.69%
Rest of World11 379.0033.4%11 183.0032.8% -1.72%
Europe7 184.0021.1%6 863.0020.1% -4.47%
United Kingdom980.002.9%975.002.9% -0.51%
GBP in Milioni
Dirigenti
Nome Titolo EtÓ Da
Emma Walmsley Chief Executive Officer & Executive Director 51 2017
Iain Mackay Chief Financial Officer & Executive Director 59 2019
Jon Ellis VP & Head-Technology Business Development 54 2019
Tony Wood Chief Scientific Officer - 2022
Amy Altshul SVP-Legal, Research & Development - -
Shobie Ramakrishnan Chief Digital & Technology Officer - 2021
James Ford Group General Counsel, Head-Legal & Compliance - 2018
Sarah-Jane Hall Group Treasurer & Senior Vice President - -
Victoria A. Whyte Secretary - 2009
Philip Thomson President-Global Affairs - 2017
Amministratori
Nome Titolo EtÓ Da
Jonathan Symonds Non-Executive Chairman 62 2019
Urs Rohner Independent Non-Executive Director 62 2015
Jesse L. Goodman, Dr. Independent Non-Executive Director 69 2016
Laurie H. Glimcher, Dr. Independent Non-Executive Director 69 2017
Charles Bancroft Senior Independent Non-Executive Director 61 2022
Anne C. Beal, Dr. Independent Non-Executive Director - 2021
Harry C. Dietz, Dr. Independent Non-Executive Director - 2022
Emma Walmsley Chief Executive Officer & Executive Director 51 2017
Hal Barron Non-Independent Non-Executive Director 58 2022
Iain Mackay Chief Financial Officer & Executive Director 59 2019
Azioni
Voto QuantitÓFlottanteAutocontrolloFlottante totale
Azione A 1 4 311 277 892 4 035 728 201 93.6% 0 0.0% 93.6%
Azionisti
NomeAzioni%
The Vanguard Group, Inc. 163 079 000 3,21%
BlackRock Fund Advisors 137 578 000 2,71%
Dodge & Cox 117 971 700 2,32%
Norges Bank Investment Management 112 415 000 2,21%
Schroder Investment Management Ltd. 87 749 738 1,73%
BlackRock Advisors (UK) Ltd. 77 718 427 1,53%
Capital Research & Management Co. (Global Investors) 74 942 865 1,47%
Legal & General Investment Management Ltd. 70 853 243 1,39%
Silchester International Investors LLP 66 609 000 1,31%
SIX SIS Ltd. 62 124 000 1,22%
Partecipazioni
NomeAzioni%Valorizzazione
VIR BIOTECHNOLOGY, INC. (VIR) 8 550 954 6,46% 217 792 798 USD
LYELL IMMUNOPHARMA, INC. (LYEL) 30 253 189 12,3% 197 250 792 USD
GLAXOSMITHKLINE PAKISTAN LIMITED (GLAXO) 263 029 794 82,6% 160 587 580 USD
GLAXOSMITHKLINE CONSUMER HEALTHCARE PAKISTAN LIMITED (GSKCH) 100 423 259 85,8% 116 964 978 USD
GLAXOSMITHKLINE S.A.E (BIOC) 76 161 378 91,2% 101 076 050 USD
THERAVANCE BIOPHARMA, INC. (TBPH) 9 644 807 12,7% 87 381 951 USD
DONG-A SOCIO HOLDINGS CO., LTD. (A000640) 409 693 6,45% 32 342 522 USD
BICYCLE THERAPEUTICS LIMITED 1 529 561 5,17% 25 666 034 USD
FULCRUM THERAPEUTICS, INC. (FULC) 1 785 714 4,37% 8 749 999 USD
ALLERGY THERAPEUTICS PLC (AGY) 10 118 000 1,57% 2 549 736 USD
Coordinate societÓ
GSK Plc
980 Great West Road
Brentford
Middlesex, Greater London TW8 9GS

Phone : +44.20.8047.5000
Fax : +44.20.8047.7807
Web : http://gsk.com
Portafoglio di marchi
In collaborazione conAllbrands.markets
Pi¨ marchi di GSK plc
Settore Prodotti farmaceutici - Altri
Var. 1genCapi. (M$)
GSK PLC-11.78%71 163
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131
NOVO NORDISK A/S4.76%240 550
MERCK & CO., INC.18.76%230 579
ASTRAZENECA PLC23.44%201 219
NOVARTIS AG-0.22%185 374
BRISTOL-MYERS SQUIBB COMPANY21.20%161 361
AMGEN INC.10.41%132 871
SANOFI-3.52%109 706
BAYER AG15.21%54 546
DAIICHI SANKYO CO., LTD.25.71%52 755
CHUGAI PHARMACEUTICAL CO., LTD3.37%47 539
TAKEDA PHARMACEUTICAL COMPANY LIMITED21.07%43 952
JIANGSU HENGRUI MEDICINE CO., LTD.-26.17%35 420
ASTELLAS PHARMA INC.8.77%27 823
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-31.37%26 844
CATALENT, INC.-14.11%19 708